A noninvasive urinary biomarker panel predicts lupus nephritis activity and response better than proteinuria, and, if further validated, may aid diagnosis and gauge treatment response, investigators ...

GLP-1 receptor agonist use is associated with benefits in a number of different disease and may help treat patients with lupus nephritis.

The new guideline also recommends faster tapering to a lower dose of glucocorticoids and a longer duration of ...

ImmuneOnco Biopharmaceuticals has received approval from China’s National Medical Products Administration for a Phase II ...

Chicago’s Cour Pharmaceuticals—recently honored as one of Fierce Biotech’s 2024 Fierce 15—is bringing its immunology mission ...

The glucose-lowering and weight-reducing drug class appears to benefit the heart and kidneys in people with lupus and lupus nephritis, independently of glucose-lowering and weight loss.

Inflammation from lupus can cause a type of kidney disease called lupus nephritis. Learn more about how lupus affects the kidneys and lupus nephritis. For some people with lupus nephritis, lupus ...

Fast Track designation is designed to expedite clinical development and regulatory review timelinesEnrolling patients in the GLEAM trial for ...

Studies investigating what is damaging the kidney in lupus nephritis point to tubulointerstitial inflammation.

which includes extrarenal lupus and lupus nephritis. Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet ...

Two studies presented at the 2024 American College of Rheumatology (ACR) Annual Meeting revealed that GLP-1 receptor agonists ...

This report report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Lupus Nephritis pipeline landscape. It covers the pipeline drug profiles, including clinical and ...